Novakand Pharma AB (publ) (LARK) — Cash Flow Quality Index

Latest as of September 2022: 0.10x

Novakand Pharma AB (publ) (LARK) has a Cash Flow Quality Index of 0.10x as of September 2022. Operating cash flow of Skr379.00K is below net income of Skr3.95 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Novakand Pharma AB (publ) cash conversion from operations to assess how effectively this company generates cash.

Cash Flow Quality Index

0.10x
Operating CF / Net Income

Operating Cash Flow

Skr379.00K
SEK

Net Income

Skr3.95 Million
SEK

Data as of

Sep 2022
Most recent filing

Novakand Pharma AB (publ) Cash Flow Quality Index (2021–2021)

Historical Cash Flow Quality Index for Novakand Pharma AB (publ) across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check LARK total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for Novakand Pharma AB (publ) (2021–2021)

Year-by-year earnings quality comparison for Novakand Pharma AB (publ). For live market cap and the full company financial profile, see Novakand Pharma AB (publ) (LARK) market capitalisation.

Year Quality Index Operating CF (SEK) Net Income YoY Change
2021 1.05x Skr22.11 Million Skr20.96 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.